358 related articles for article (PubMed ID: 9060539)
1. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
2. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
3. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
[TBL] [Abstract][Full Text] [Related]
5. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
[TBL] [Abstract][Full Text] [Related]
6. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
Doyle C; Crump M; Pintilie M; Oza AM
J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
[TBL] [Abstract][Full Text] [Related]
7. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
[TBL] [Abstract][Full Text] [Related]
8. Costs associated with resource utilization during the palliative phase of care: a Canadian perspective.
Dumont S; Jacobs P; Fassbender K; Anderson D; Turcotte V; Harel F
Palliat Med; 2009 Dec; 23(8):708-17. PubMed ID: 19837702
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
[TBL] [Abstract][Full Text] [Related]
10. Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy.
Gilbert L; Ramanakumar AV; Festa MC; Jardon K; Zeng X; Martins C; Shbat L; Alsoud MA; Borod M; Wolfson M; Papaioannou I; Basso O; Sampalis J
J Comp Eff Res; 2020 Jun; 9(8):537-551. PubMed ID: 32223298
[No Abstract] [Full Text] [Related]
11. Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer.
Havrilesky LJ; Krivak TC; Mucenski JW; Myers ER
Am J Obstet Gynecol; 2010 Aug; 203(2):160.e1-7. PubMed ID: 20417480
[TBL] [Abstract][Full Text] [Related]
12. The end of life costs for Medicare patients with advanced ovarian cancer.
Urban RR; He H; Alfonso R; Hardesty MM; Goff BA
Gynecol Oncol; 2018 Feb; 148(2):336-341. PubMed ID: 29208368
[TBL] [Abstract][Full Text] [Related]
13. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
Lewin SN; Buttin BM; Powell MA; Gibb RK; Rader JS; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Nov; 99(2):261-6. PubMed ID: 16140364
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
Ojeda B; de Sande LM; Casado A; Merino P; Casado MA
Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the prostate: an expensive way to die.
Piper NY; Kusada L; Lance R; Foley J; Moul J; Seay T
Prostate Cancer Prostatic Dis; 2002; 5(2):164-6. PubMed ID: 12497008
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
19. Treatment pathways, resource use and costs in the management of small cell lung cancer.
Oliver E; Killen J; Kiebert G; Hutton J; Hall R; Higgins B; Bourke S; Paschen B
Thorax; 2001 Oct; 56(10):785-90. PubMed ID: 11562518
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.
Bloomfield DJ; Krahn MD; Neogi T; Panzarella T; Smith TJ; Warde P; Willan AR; Ernst S; Moore MJ; Neville A; Tannock IF
J Clin Oncol; 1998 Jun; 16(6):2272-9. PubMed ID: 9626231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
